Attached files

file filename
EX-99.1 - EX-99.1 - KERYX BIOPHARMACEUTICALS INCd147280dex991.htm
EX-99.2 - EX-99.2 - KERYX BIOPHARMACEUTICALS INCd147280dex992.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 25, 2016

 

 

Keryx Biopharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-30929   13-4087132

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

One Marina Park Drive, 12th Floor

Boston, Massachusetts 02210

(Address of Principal Executive Offices)

(617) 466-3500

(Registrant’s telephone number, including area code)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act.

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 


Item 2.02.        Results of Operations and Financial Condition.

On February 25, 2016, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing its results of operations for the fourth quarter and year ended December 31, 2015. Keryx also announced that on February 25, 2016 at 8:00 a.m. ET, it will host an investor conference call to discuss the Company’s fourth quarter and year-end 2015 financial results and provide a business outlook for 2016. A copy of such press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference. A copy of the PowerPoint presentation to be used on the investor conference call is being furnished as Exhibit 99.2 to this report and is incorporated herein by reference.

The information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.        Financial Statements And Exhibits.

 

(d) Exhibits.

The following exhibits are furnished herewith:

 

99.1    Press release issued by Keryx Biopharmaceuticals, Inc., dated February 25, 2016.
99.2    PowerPoint presentation to be presented by Keryx Biopharmaceuticals, Inc. on February 25, 2016.


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Keryx Biopharmaceuticals, Inc.
    (Registrant)
Date: February 25, 2016    
    By:                

/s/ Brian Adams

      Brian Adams
      General Counsel and Corporate Secretary


 

INDEX TO EXHIBITS

 

Exhibit

Number

  

Description

 

99.1

   Press release issued by Keryx Biopharmaceuticals, Inc., dated February 25, 2016.
99.2    PowerPoint presentation to be presented by Keryx Biopharmaceuticals, Inc. on February 25, 2016.